<DOC>
	<DOC>NCT02254304</DOC>
	<brief_summary>This is a Phase 4, interventional, multicenter study of subcutaneous Rebif® (interferon beta-1a) using RebiSmart™ device to assess effectiveness and adherence of treatment in subjects with clinically isolated syndrome (CIS) or relapsing multiple sclerosis (RMS).</brief_summary>
	<brief_title>Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ (PROCEED)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Male and female subjects between 18 to 65 years of age Female subjects must be neither pregnant nor breastfeeding and must lack childbearing potential as defined in the protocol Subjects diagnosed with CIS or RMS according to the revised McDonald criteria (2010) Treatmentnaive subjects or subjects treated with Rebif® multidose injected by RebiSmart™ for no longer than 6 weeks prior to Baseline visit Subjects that are able to selfinject with RebiSmart™ (in the opinion of the physician) Subjects with Expanded Disability Status Scale (EDSS) score less than (&lt;) 6 (inclusive) at Baseline Signed informed consent and subject data collection form Subjects experiencing a relapse within 30 days before Baseline Participation in other studies within 30 days before Baseline Received any MS therapy within 6 months prior to study enrolment (for example, other diseasemodifying drugs: immunomodulatory, immunosuppressive agents or combination therapy) with the exception of Rebif® multidose injected by RebiSmart™ Any visual or physical impairment that precludes the subject from selfinjecting the treatment using the RebiSmart™ Pregnancy and breastfeeding Serious or acute heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure, as per investigator opinion Current or past (within the last 2 years) history of alcohol or drug abuse Have any contraindications to treatment with interferon beta1a according to Summary of Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsing multiple sclerosis</keyword>
	<keyword>Clinically isolated syndrome</keyword>
	<keyword>RMS</keyword>
	<keyword>CIS</keyword>
	<keyword>RebiSmart™</keyword>
	<keyword>Rebif®</keyword>
	<keyword>Interferon beta-1a</keyword>
</DOC>